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Abstract
Background: Increased serum neopterin had been described in older age two decades ago. Neopterin is a
biomarker of systemic adaptive immune activation that could be potentially implicated in metabolic syndrome
(MetS). Measurements of waist circumference, triglycerides, high-density lipoprotein cholesterol (HDLC), systolic and
diastolic blood pressure, glycated hemoglobin as components of MetS definition, and plasma total neopterin
concentrations were performed in 594 participants recruited in the European Prospective Investigation into Cancer
and Nutrition (EPIC).
Results: Higher total neopterin concentrations were associated with reduced HDLC (9.7 %, p < 0.01 for men and
9.2 %, p < 0.01 for women), whereas no association was observed with the rest of the MetS components as well as
with MetS overall (per 10 nmol/L: OR = 1.42, 95 % CI = 0.85-2.39 for men and OR = 1.38, 95 % CI = 0.79-2.43).
Conclusions: These data suggest that high total neopterin concentrations are cross-sectionally associated with
reduced HDLC, but not with overall MetS.
Keywords: Neopterin, Cell-mediated immunity, Metabolic syndrome
Background
Neopterin, a biomarker of systemic adaptive immune acti-
vation, is synthesized by monocyte-derived macrophages
and dendritic cells upon stimulation of interferon-gamma
(IFN-γ) and is considered a reliable proxy to assess the
rate of IFN-γ production [1–4]. The concentrations of
neopterin increase with the dose of interferon, thereby
help to monitor the activity of INF-γ inducible inflamma-
tion. Thus, the measurement of neopterin concentrations
in body fluids provides information about activation of
T-helper cell derived systemic adaptive immune activa-
tion [5]. As high neopterin is associated with increased
production of reactive oxygen species, neopterin can
also be regarded as an indicator for oxidative stress due
to immune activation [6].
Neopterin has been used clinically in the assessment
of bacterial and viral infections, autoimmune diseases,
and malignant conditions [7]. Increased blood neop-
terin concentrations had been described in older age
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[8, 9] and have been positively related to aging-related
chronic disorders, including metabolic syndrome (MetS)
[3], cancer, cardio-vascular disease, as well as overall
mortality [2–4, 10–13].
An emerging field of research - immunometabolism -
recognizes the existence of an interplay between immun-
ity, inflammation, and impaired metabolism [14]. Central
to this theory, inflammation and immune activation are
involved in the development of obesity, insulin resist-
ance and potentially also in MetS [14–16]. Despite
biological plausibility, only a few epidemiological studies
have explored the relation between neopterin and
selected metabolic factors. In a study of 3946 patients
with acute coronary syndrome, higher plasma concentra-
tions of neopterin were associated with older age, a prior
history of hypertension or diabetes, lower low-density
lipoprotein cholesterol levels, and higher high-sensitivity
C-reactive protein (hsCRP) levels [17]. In another study
among 592 patients with high prevalence of MetS, plasma
neopterin concentrations were correlated, though weakly,
with abdominal obesity, high-density lipoprotein choles-
terol (HDLC), and insulin resistance [2]. Similarly, a weak
correlation between neopterin and abdominal obesity was
reported in another patient cohort of 477 middle-aged
and older white individuals at high risk for type 2 diabetes
and cardiovascular disease [18].
It remains unclear whether the potential association of
neopterin with MetS and its components, may be inde-
pendent of age and markers of chronic inflammation
such as hsCRP. Such knowledge may provide important
insights into the potential link between immune activa-
tion and impaired metabolism. Therefore, the aim of the
study was to investigate the association of plasma total
neopterin concentrations with MetS and its components
in the European Prospective Investigation into Cancer
and Nutrition (EPIC) cohort.
Results
Overall, the geometric mean of total neopterin concen-
trations in the study population were 18.74 (standard
deviations, SD: 1.50) for men and 18.63 (SD: 1.40) for
women. Table 1 shows the characteristics of the study
population.
Table 2 presents the Spearman’s partial correlation
coefficients of clinical markers of MetS and total neop-
terin concentrations. Total neopterin was inversely
correlated with pyridoxal 5′-phosphate (PLP) and HDLC
but positively correlated with hsCRP.
High total neopterin concentrations were associated with
lower HDLC, but not with other components of MetS
(Table 3). After mutual adjustment, the mean total neop-
terin concentrations remained different according to HDLC
categories (p < 0.01 for both men and women). Figure 1
shows the adjusted means and 95 % CI of total neopterin
by increasing number of MetS components. The average
differences per component was 4.0 % (Pdifference = 0.07) for
men and 0.8 % (Pdifference = 0.64) for women.
In our study, increased total neopterin was associ-
ated with reduced HDLC (OR per 10 nmol/L = 2.22,
95 % CI = 1.24-3.97 for men and OR per 10 nmol/L = 2.82,
95 % CI = 1.68-4.73 for women), and these associations
were independent of PLP (Table 4). Further adjustment
for hsCRP did not change the results (OR per 10 nmol/
L = 2.14, 95 % CI = 1.17-3.91 for men and OR per 10
nmol/L = 2.70, 95 % CI = 1.58-4.61, data not shown). In-
creased plasma total neopterin was not associated with
overall MetS, defined as presence of any three of the MetS
components (OR per 10 nmol/L = 1.42, 95 % CI = 0.85-2.39
for men and OR per 10 nmol/L = 1.38, 95 % CI = 0.79-2.43
for women).
Discussion
In this study, high total neopterin concentrations were
associated with reduced HDLC, but not with overall
MetS. These data indicate that immune activation may
be related to lipid changes; however, the cross-sectional
nature of the study does not provide sufficient informa-
tion for interpreting the direction of these relations.
Previously only three studies investigated the associ-
ation of neopterin concentrations with clinical markers
of MetS; however, these studies were conducted in
participants with underlying diseases, including cardio-
vascular disease, type 2 diabetes and MetS [2, 18, 19]. In
agreement with the study of Oxengrug et al. 2011 [2],
we observed an inverse association of total neopterin
with HDLC.
Our data suggest an inverse association of total neop-
terin with HDLC, as well as low-density lipoprotein
cholesterol and total cholesterol. This association was
independent of age, sex, EPIC study center and smoking
status as well as PLP and hsCRP levels. Similar findings
have been reported, in patients with HIV infection [20],
cardiovascular diseases [4] and MetS [2]. HDLC helps to
remove excess cholesterol from peripheral tissue and
transport it to the liver for excretion. The functions of
HDL include anti-inflammatory and anti-oxidant activities
[21]. If the function is impaired, cholesterol accumulates
in peripheral tissue and causes inflammation and athero-
sclerosis. Despite the concept of HDL dysfunction evolved
over the last decades, little is known on factors that under-
line possible alterations between functional and dysfunc-
tional HDL. Recently, immunity was suggested as one of
the main pathophysiological pathways of HDLC function-
ality via modulating cholesterol content in immune cells
[22]. It has been shown that inhibition of cholesterol efflux
mechanisms in macrophages promotes an inflammatory
phenotype in these cells [23]. The raised neopterin levels
may indicate activated immune response in individuals
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with low HDL cholesterol levels. Neopterin had been
associated with cardiovascular events [4, 24, 25], suggest-
ing a potential involvement of adaptive immunity and
inflammation in modulating the association between
cholesterol metabolism and cardio-metabolic risk. From a
practical perspective, measurement of neopterin in addition
to HDLC may aid in identifying HDL anti-inflammatory/
proinflammatory function and could likely yield important
additional information beyond that available from simple
measurement of HDLC in an individual. However, future
studies are needed in order to evaluate potential prac-
tical implication of these findings. Of note, despite the
association with HDLC, we observed no association
with previous diagnosis of hyperlipidemia (data not
shown). This can be partly explained by the observation
that total neopterin concentrations were lower in those
who used lipid-lowering drugs [4].
Previous studies have reported positive associations be-
tween neopterin and waist circumference [2, 10, 18, 26, 27].
In one of these; however, such association disappeared after
adjustment for other metabolic biomarkers [18]. Thewissen
et al. (2011) reported that the association between abdom-
inal fat and neopterin - considered a marker of adaptive
immune activation - was mediated, by elevations in hsCRP
and other immune activation markers [18]. They hypothe-
sized that it is not merely an increased mass of adipose
tissue that directly leads to attenuation of insulin action,
but rather adipose tissue inflammation mediated by
activated immune system in obese individuals that leads
to insulin resistance. In our study, we only observed a
non-statistically significant marginal association be-
tween abdominal obesity and total neopterin concen-
trations. Further prospective studies are needed to test
this hypothesis.
Similarly to a previous report [4], we found no associ-
ation between total neopterin concentrations and triglyc-
erides (TG). There was no association between total
neopterin concentrations and measured systolic or dia-
stolic blood pressure (BP), including pre-defined cutoffs
for hypertension. There have been reports suggesting
Table 1 Characteristics of the study population
Total Men Women
N % N % N %
Age, mean (SD) 57.59 (8.24) 58.24 (7.81) 57.04 (8.55)
Education
None or primary school completed 247 42 118 44 129 40
Technical/professional school 123 21 58 21 65 20
Secondary school 83 14 16 6 67 21
Longer education 119 20 66 24 53 16
Not specified 22 4 12 4 10 3
Smoking status
Never 273 46 80 30 193 60
Former 196 33 125 46 71 22
Current 118 20 61 23 57 18
Unknown 7 1 4 1 3 1
Physical activity
Low 102 17 60 22 42 13
Medium 121 20 62 23 59 18
High 139 23 53 20 86 27
Very high 205 35 77 29 128 40
Missing 27 5 18 7 9 3
Waist circumference, cm, mean (SD) 87.22 (11.83) 94.37 (9.33) 81.41 (10.38)
Tryglicerides, mmol/L, mean (SD) 1.19 (0.94) 1.29 (1.07) 1.10 (0.80)
High-density lipoprotein cholesterol, mmol/L, mean (SD) 1.43 (0.39) 1.29 (0.36) 1.54 (0.38)
Systolic blood pressure, mmHg, mean (SD) 128.93 (16.77) 131.41 (15.70) 127.14 (17.31)
Diastolic blood pressure, mmHg, mean (SD) 79.72 (9.84) 81.94 (9.76) 78.12 (9.60)
HbA1c (%), mean (SD) 5.74 (0.61) 5.77 (0.63) 5.71 (0.60)
Nopterin (nmol/L) , mean (SD) 20.07 (7.90) 20.39 (8.37) 19.81 (7.49)
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Table 2 Spearman partial correlation coefficients (r)1 between total neopterin, pyridoxal 5'-phosphate (PLP) and markers of metabolic factors
PLP, μmol/L Waist circumference, cm Tryglicerides,
mmol/L
High-density lipoprotein
cholesterol, mmol/L
Systolic blood
pressure (mmHg)
Diastolic blood
pressure, mmHg
HbA1c (%) hsCRP, mg/L
ρ p ρ p ρ p ρ p ρ p ρ p ρ p ρ p
Men
Neopterin, nmol/L −0.13 0.04 0.24 <0.01 −0.07 0.29 −0.18 0.01 0.09 0.22 0.16 0.04 0.01 0.91 0.18 0.01
PLP, μmol/L 0.08 0.24 −0.04 0.55 0.21 <0.01 −0.18 0.07 −0.05 0.57 −0.09 0.35 −0.11 0.11
Waist circumference, cm 0.26 <0.01 −0.23 <0.01 0.26 <0.01 0.28 <0.01 0.12 0.15 0.21 0.02
Tryglicerides, mmol/L −0.35 <0.01 0.15 0.04 0.24 0.00 0.06 0.50 0.02 0.79
High-density lipoprotein
cholesterol, mmol/L
−0.18 0.01 −0.17 0.02 0.04 0.58 −0.17 0.01
Systolic blood pressure, mmHg 0.66 <0.01 0.11 0.27 0.08 0.29
Diastolic blood pressure, mmHg −0.01 0.89 0.07 0.36
HbA1c (%) 0.07 0.45
Women
Neopterin, nmol/L −0.15 0.01 0.10 0.09 0.02 0.68 −0.24 <0.01 −0.05 0.43 −0.07 0.28 −0.11 0.23 0.15 0.01
PLP, μmol/L −0.06 0.29 −0.08 0.17 0.14 0.02 −0.08 0.44 −0.03 0.78 0.25 0.01 −0.20 <0.01
Waist circumference, cm 0.31 <0.01 −0.28 <0.01 0.25 <0.01 0.21 <0.01 0.14 0.15 0.27 <0.01
Tryglicerides, mmol/L −0.35 <0.01 0.16 0.01 0.13 0.03 0.07 0.50 0.15 0.12
High-density lipoprotein
cholesterol, mmol/L
−0.04 0.48 0.01 0.89 0.14 0.12 −0.09 0.12
Systolic blood pressure, mmHg 0.64 <0.01 0.01 0.95 0.19 <0.01
Diastolic blood pressure, mmHg 0.03 0.76 0.04 0.56
HbA1c (%) 0.00 0.99
1.The partial correlation coefficients were adjusted for age at blood collection (years), sex, EPIC study centers, and smoking status (never, former, current, and unknown)
Abbreviations: PLP pyridoxal 5'-phosphate, WC waist circumference, TG triglycerides, HDLC high-density lipoprotein cholesterol, SBP systolic blood pressure, DBP
diastolic blood pressure, hsCRP high-sensitivity C-reactive protein, HbA1c glycatred hemoglobin
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Table 3 Adjusted geometric means and 95 % confidence intervals (95 % CI) of the means of total neopterin by levels of pyridoxal
5'-phosphate (PLP) and markers of metabolic factors
Men Women
Mean1 95 % CI Difference2 p Mean1 95 % CI Difference2 p
PLP, μmol/L
T1 (M: <=28.1 (Median:21.4); F: <=24.5 (Median:19.6)) 18.09 15.67 20.89 15.53 13.42 17.98
T2 (M: 28.1-44.9 (Median:34.7); F: 24.5-38.9 (Median:30.4)) 17.26 14.81 20.11 −4.7 % 0.43 14.68 12.81 16.83 −7.3 % 0.11
T3 (M: >44.9 (Median:63.5); F: >38.9 (Median:53.9)) 16.72 14.52 19.24 −7.9 % 0.18 16.71 14.60 19.13 −13.0 % 0.01
Per tertile −3.9 % 0.18 −6.5 % 0.01
Waist circumference (cm)
T1 (M: <=91.01 (Median:86.45); F: <=76.77 (Median:71.50)) 17.26 14.90 19.98 16.03 13.77 18.67
T2 (M: 91.01-98.71 (Median:95); F: 76.77-85.51 (Median:80.50)) 18.93 16.37 21.89 9.2 % 0.12 16.25 13.91 18.98 1.3 % 0.77
T3 (M: >98.71 (Median:104); F: >85.51 (Median:93)) 19.17 16.44 22.37 10.5 % 0.11 16.93 14.62 19.61 5.4 % 0.26
Per tertile 5.3 % 0.11 2.7 % 0.27
Triglyceride (mmol/L)
<1.7 17.07 14.95 19.49 16.24 13.94 18.92
1.7-3.4 17.09 14.62 19.99 0.2 % 0.98 16.21 14.01 18.75 −3.7 % 0.53
> = 3.4 21.66 16.99 27.61 23.8 % 0.03 16.29 13.94 19.03 9.3 % 0.48
Per mmol/L 5.9 % 0.03 2.3 % 0.56
High-density lipoprotein cholesterol (mmol/L)
T1 (M: <=1.10 (median:0.98); F: <=1.33 (median:1.18)) 19.72 17.09 22.75 18.52 15.97 21.47
T2 (M: 1.10-1.34 (median:1.21); F: 1.33-1.62 (median:1.49)) 16.52 14.33 19.04 −17.7 % 0.00 15.73 13.62 18.15 −16.4 % 0.00
T3 (M: >1.34 (median:1.60); F: >1.62 (median:1.87)) 16.29 14.15 18.75 −19.1 % 0.00 15.44 13.36 17.85 −18.2 % <0.01
Per tertile −9.7 % 0.00 −9.2 % <0.01
Low-density lipoprotein cholesterol (mmol/L)
Q1 (M: <3.88 (median:3.37); F: <3.88 (median:3.34)) 18.96 16.39 21.94 16.65 14.49 19.14
Q2 (M: 3.88-4.70 (median:4.25); F: 3.88-4.90 (median:4.34)) 16.79 14.64 19.27 −12.2 % 0.03 15.60 13.59 17.92 −6.5 % 0.17
Q3 (M: ≥4.70 (median:5.29); F: ≥4.90 (median:5.55)) 16.63 14.37 19.26 −13.1 % 0.03 14.76 12.83 16.98 −12.1 % 0.02
Per tertile −6.6 % 0.03 −6.0 % 0.02
Total cholesterol (mmol/L)
Q1 (M: <5.74 (median:5.16); F: <5.94 (median:5.29)) 19.19 16.58 22.21 16.61 14.43 19.12
Q2 (M: 5.74-6.59 (median:6.17); F: 5.94-6.99 (median:6.49)) 16.61 14.48 19.06 −14.4 % 0.01 15.47 13.46 17.79 −7.1 % 0.15
Q3 (M: ≥6.59 (median:7.32); F: ≥6.99 (median:7.69)) 16.85 14.53 19.54 −13.0 % 0.03 15.03 13.07 17.29 −10.0 % 0.05
Per tertile −6.8 % 0.03 −4.9 % 0.05
Blood pressure
Systolic BP
<=123 16.87 14.59 19.51 16.20 13.68 19.18
123-139 17.01 14.66 19.74 0.8 % 0.89 16.15 13.66 19.09 −0.3 % 0.95
>139 18.14 15.50 21.24 7.3 % 0.28 15.75 13.31 18.64 −2.8 % 0.61
Per tertile 3.6 % 0.27 −1.4 % 0.60
Diastolic BP
<=76 16.76 14.53 19.34 16.43 13.88 19.46
76-85 16.93 14.59 19.65 1.0 % 0.87 16.11 13.68 18.98 −0.02 0.70
>85 18.50 15.85 21.60 9.9 % 0.12 15.32 12.90 18.19 −0.07 0.19
Per tertile 4.9 % 0.11 −3.5 % 0.19
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that neopterin could be a predictive marker for car-
diovascular events [4, 19, 24, 25, 28–31], including an
elevated diastolic BP [29, 32]. However, its associations
with hypertension (or BP) have been inconsistent across
studies. In this context, our results might suggest that
although hypertension is an important component of
cardiovascular diseases, it might not be directly associated
with inflammation or IFN-γ mediated inflammation.
Previous studies have also reported that neopterin
concentrations were positively associated with glucose
Table 3 Adjusted geometric means and 95 % confidence intervals (95 % CI) of the means of total neopterin by levels of pyridoxal
5'-phosphate (PLP) and markers of metabolic factors (Continued)
Systolic BP ≥130 or diastolic BP ≥85 mmHg or diagnosis for hypertension
No 16.89 14.60 19.54 16.01 14.06 18.25
Yes 17.29 14.83 20.15 2.3 % 0.66 14.90 12.94 17.16 −7.2 % 0.08
HbA1C
T1 (M < 5.5; F < 5.5) 17.96 15.72 20.50 18.24 14.72 22.60
T2 (M: 5.5-5.9; F: 5.5-5.8) 17.00 14.81 19.51 −5.5 % 0.43 17.75 14.18 22.22 −2.7 % 0.67
T3 (M≥ 5.9; F≥ 5.8) 17.51 15.07 20.34 −2.5 % 0.74 16.73 13.29 21.06 −8.7 % 0.22
Per tertile −1.4 % 0.71 −4.2 % 0.23
<5.7 % 17.77 15.61 20.24 0.67 17.85 14.44 22.08 0.84
≥5.7 % 17.32 15.30 19.62 −2.6 % 17.66 14.19 21.98 −1.1 %
HbA1C ≥5.7 % or diagnosis for diabetes
No 16.99 14.74 19.59 0.80 15.78 13.81 18.05 0.37
Yes 17.21 14.67 20.18 1.3 % 15.16 13.09 17.57 −4.0 %
1.The means were calculated by exponentiating the natural-log transformed means, which were estimated from multiple linear regression and adjusted for age at
blood collection (years), sex, country, education (none or primary school completed, technical or professional school, secondary school, above secondary school,
and not specified), smoking status (never, former, current, and unknown), and physical activity (low, medium, high, very high, missing)
2.The differences compared to the first category of each variable
Abbreviations: T tertile, PLP pyridoxal 5'-phosphate, BP blood pressure, HbA1C glycated hemoglobin
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Fig. 1 Adjusted means1 and 95 % confidence intervals of total neopterin by increasing number of metabolic syndrome components2. 1. The
means were calculated by exponentiating the natural-log transformed means, which were estimated from multiple linear regression and adjusted
for age at blood collection (years), sex, education (none or primary school completed, technical or professional school, secondary school, above
secondary school, and not specified), smoking status (never, former, current, and unknown), and physical activity (low, medium, high, very high,
missing). 2. The markers were considered abnormal when waist circumference ≥94 cm in men and ≥88 in women; triglycerides ≥1.7 mmol/L;
high-density lipoprotein cholesterol <1.03 in men, <1.29 mmol/L in women; systolic blood pressure ≥130 or diastolic ≥85 mmHg; and
HbA1c ≥5.7 % or self-reported ever physician diagnosed diabetes
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Table 4 Association between total neopterin and metabolic syndrome (MetS)1 and its components
MetS components Total Neopterin, nmol/L, Men
T12 T22 T32 Per 10 nmol/L
Normal Abnormal OR4 Normal Abnormal OR4 95 % CI Normal Abnormal OR4 95 % CI OR4 95 % CI Ptrend
Waist circumference ≥94 cm in men 52 37 1.00 39 51 2.00 (1.00, 3.99) 31 49 2.12 (1.01, 4.42) 1.64 (0.99, 2.73) 0.05
Triglycerides ≥1.7 mmol/L 77 22 1.00 67 22 1.21 (0.57, 2.56) 58 22 1.14 (0.52, 2.50) 1.08 (0.64, 1.84) 0.77
High-density lipoprotein cholesterol ,<1.03 in men 90 9 1.00 69 21 2.75 (1.13, 6.70) 56 24 3.71 (1.48, 9.32) 2.22 (1.24, 3.97) 0.01
Systolic blood pressure ≥130 or diastolic ≥85 mmHg or
diagnosis for hypertension
49 50 1.00 50 40 0.93 (0.43, 2.04) 37 43 0.82 (0.34, 1.95) 0.87 (0.48, 1.59) 0.65
HbA1c ≥5.7 % or self-reported ever physician diagnosed
diabetes
69 30 1.00 53 37 1.62 (0.83, 3.15) 50 30 1.47 (0.72, 3.01) 1.28 (0.79, 2.08) 0.32
Any three of the above 86 13 1.00 73 18 2.02 (0.95, 4.30) 61 19 1.82 (0.83, 3.99) 1.42 (0.85, 2.39) 0.18
MetS components Total Neopterin, nmol/L, Women
T12 T22 T32 Per 10 nmol/L
Normal Abnormal OR4 Normal Abnormal OR4 95 %
CI
Normal Abnormal OR4 95 %
CI
OR4 95 %
CI
Ptrend
Waist circumference ≥80 cm in women3 68 51 1.00 49 57 1.48 (0.83, 2.61) 44 50 1.27 (0.70, 2.31) 1.21 (0.76, 1.94) 0.43
Triglycerides ≥1.7 mmol/L 104 17 1.00 90 15 0.97 (0.43, 2.16) 80 15 0.87 (0.38, 2.00) 0.89 (0.46, 1.73) 0.74
High-density lipoprotein cholesterol, <1.29 mmol/L in women 102 19 1.00 72 34 2.90 (1.48, 5.70) 58 37 4.05 (2.04, 8.03) 2.82 (1.68, 4.73) <0.01
Systolic blood pressure ≥130 or diastolic ≥85 mmHg or
diagnosis for hypertension
73 50 1.00 64 42 0.80 (0.43, 1.51) 60 35 0.66 (0.33, 1.30) 0.72 (0.42, 1.23) 0.22
HbA1c ≥5.7 % or self-reported ever physician diagnosed
diabetes
90 30 1.00 80 24 0.90 (0.46, 1.74) 70 25 1.08 (0.55, 2.10) 1.06 (0.62, 1.81) 0.83
Any three of the above 109 14 1.00 90 16 1.43 (0.71, 2.91) 77 18 1.53 (0.74, 3.16) 1.38 (0.79, 2.43) 0.26
1.Metabolic syndrome is defined based on the joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart
Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Analysis is based on an alternate MetS definition modified to include HbA1C instead of
glucose as a marker for impaired glucose metabolism (22)
2.Tertile 1 (T1, nmol/L): ≤17.20 for men and ≤16.30 for women; tertile 2 (T2): 17.20-22.60 for men and 16.30-21.90 for women; tertile 3 (T3): >22.60 for men and >21.90 for women. Medians (nmol/L): 13.70 for men and
14.18 for women in T1, 19.60 for men and 19.65 for women in T2, and 28.20 for men and 26.80 for women in T3
3.Recent American Heart Association/National Heart, Lung, and Blood Institute guidelines for metabolic syndrome recognize an increased risk for CVD and diabetes at waist-circumference thresholds of ≥94 cm in men
and ≥80 cm in women and identify these as optional cut points for individuals or populations with increased insulin resistance (22)
4.ORs were adjusted for age at blood collection (years), sex, country, education (none or primary school completed, technical or professional school, secondary school, above secondary school, and not specified),
smoking status (never, former, current, and unknown), and physical activity (low, medium, high, very high, missing)
Abbreviations: MetS metabolic syndrome, T tertile, OR odds ratio
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concentrations [10]. However, we did not observe an
association between total neopterin concentrations and
diabetes, either using the glycated haemoglobin (HbA1C),
a marker of long-term blood glucose levels, or with self-
reported diabetes. Similar findings have been obtained in a
small saline-controlled crossover study on six healthy men
(mean age 22 years) for IFN-γ [33].
Limitations of the present study have to be taken into
account. First, the mean and median concentrations of
total neopterin in this study population was somewhat
higher than previously reported [2, 27]. An explanation is
that our assay measures total neopterin, which is the sum
of 7,8-dihydroneopterin and neopterin, in contrast to
ELISA method which measures only neopterin. Neverthe-
less, both neopterin and total neopterin reflect inflamma-
tion and the associations between total neopterin and
hsCRP, as well as the other metabolic biomarkers were
comparable with previous reports (9). In addition, in our
data no unexpected correlations between neopterin and
basic characteristics were observed, as well as main find-
ings were also in line with the previous reports. Secondly,
the study population included controls of a nested case–
control study; therefore, it may not be representative of
the general population. However, when compared to the
overall EPIC population, we have not seen major differ-
ences according to baseline characteristics, except for that
our study population was slightly older, included a higher
proportion of men, and a higher proportion of smokers.
The range of the concentration of total neopterin reported
here may not be fully representative of the general popula-
tion. Thirdly, the relation between total neopterin and
MetS components was assessed within the context of a
cross-sectional study design, which does not allow infer-
ence about the direction of the associations. Finally, about
70 % of the study participants provided non-fasting
blood samples, which may have affected the TG levels;
however, we have been accounting for fasting status
and found essentially the same results after excluding
non-fasting participants.
Conclusions
In conclusion, high total neopterin concentrations are
associated with reduced HDLC, but not with overall MetS.
These data support the emerging knowledge on the inter-
play of immune response and cholesterol metabolism. Fu-
ture studies are warranted to better understand the
potential role of these interrelations in chronic disease
development.
Methods
Study population
The design of the EPIC cohort has been described previ-
ously [34]. In brief, EPIC recruited 518,408 volunteers from
23 centers in 10 countries (Sweden, Denmark, Norway, the
Netherlands, United Kingdom, France, Germany, Spain,
Italy, and Greece) between 1992 and 2000. The eligibility
criteria for participation was primarily decided within each
cohort. In general, apparently healthy, middle-aged subjects
who agreed to participate in the study and to have their
health status followed up for the rest of their lives, were
recruited. The questionnaires were completed and the
blood samples were taken at recruitment.
Assessment of anthropometry and lifestyle data
The lifestyle questionnaires, which were completed by
participants, included questions on diet, education, oc-
cupation, previous illnesses, alcohol, tobacco consump-
tion, and physical activity. Informed consent forms were
filled at each local center and the study was approved by
the Institutional Review Board at the International
Agency for Research on Cancer (IARC) and the local
ethics committees. Waist circumference was measured
either at the narrowest torso circumference or at the
midpoint between the lower ribs and iliac crest. Systolic
BP and diastolic BP were measured by trained personnel.
Two readings were performed on the right arm in a
sitting position (spaced by 1–5 minutes) by use of a
standard mercury manometer or oscillometric device.
To avoid any possible white coat effect, we used the
second reading, and when unavailable, the first reading.
Definition of MetS
The definition of MetS and its components have been
described previously [35]. In general, we followed the
harmonized definition published by Alberti et al. in 2009
[36] with slight modification in determining abnormal
glucose metabolism. Briefly, MetS was defined as having
any three of the following five components: 1) abdom-
inal obesity, i.e. waist circumference is greater than or
equal to 94 cm in men or 80 cm in women; 2) elevated
TG, i.e. greater than or equal to 1.7 mmol/L, after
correction for the fasting status of the study subjects;
that is, subtracting the sex-specific geometric mean
difference between non-fasting and fasting subjects
from the individual levels of non-fasting subjects; 3)
reduced HDLC, i.e. less than 1.03 mmol/L in men
and 1.29 mmol/L in women; 4) elevated BP, i.e. systolic BP
130 mmHg or more or diastolic BP 85 mmHg or more or
self-reported physician diagnosed hypertension; and 5)
abnormal glucose metabolism, i.e. self-reported physician
diagnosed diabetes status or HbA1c of 5.7 %, which corre-
sponds to fasting plasma glucose levels of 100 mg/dL .
Laboratory assays
Plasma concentration of total neopterin (7,8-dihydroneop-
terin + neopterin) and PLP was determined by liquid
chromatography-tandem mass spectrometry (LC-MS/MS)
[37] at Bevital A/S (http://www.bevital.no), Bergen, Norway.
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Serum hsCRP was measured by a high-sensitivity assay
(Beckman-Coulter, Woerden, the Netherlands), and the
HDLC and TG concentrations by a colorimetric method,
on a Synchron LX-20 Pro autoanalyzer (Beckman-Coulter,
[38]). Measurements of HbA1c in erythrocyte hemolysate
were carried out using high-performance liquid chroma-
tography with a Bio-Rad Variant II instrument (Bio-Rad
Laboratories, Hercules, California) [39]. The within and
between day coefficients of variance (CV) were 3-10 % for
total neopterin and PLP [37]. The inter-assay CV were
6.0 % and 6.5 % at CRP concentrations of 1.16 and
1.89 mg/L, respectively, 4.1 %, 3.4 %, and 3.6 % at HDLC
concentrations of 0.62, 1.20, and 1.65 mmol/L, respectively,
and 3.3 %, 2.1 %, and 2.0 % at TG concentrations at 86.6,
165.9, and 227.0 mg/dL, respectively. The intra-batch CV
was 2.5 % for HbA1c [39].
Statistical analysis
The current analysis is based on 845 subjects (375 men
and 470 women) who served as controls in matched
case–control studies of colorectal cancer nested within
the EPIC. The original aims of the nested case–control
studies were to explore the risk of colon and rectal can-
cer in relation to MetS [35] and one-carbon metabolism
biomarkers [40, 41]. MetS component measurements
were not available subjects from Norway and Malmo
center of Sweden. We further excluded 207 subjects
who received treatment or the treatment information
were missing for hyperlipidemia (n = 94), hypertension
(n = 175), or diabetes (n = 15). Additional 44 subjects
were excluded because their total neopterin measure-
ments were not available. The final sample size for the
analysis was 594.
The correlation between total neopterin and compo-
nents were examined by Spearman’s partial correlation
coefficients (r), adjusted for age, sex, country, and smok-
ing status. Adjusted means for total neopterin according
to tertiles of each MetS component were calculated
using multiple linear regression models. Because the
range of the middle category of TG is narrow, we
categorized TG at 1.7 and 3.4 mmol/L. The dependent
variable, total neopterin concentrations, was natural log-
transformed and the normality assumption was tested by
graphic examination of the residual distribution. The
models were adjusted for age at blood collection (years),
sex, country, education (none or primary school com-
pleted, technical or professional school, secondary school,
above secondary school, and not specified), smoking
status (never, former, current, and unknown), and physical
activity (low, medium, high, very high, and missing). The
adjusted means were also assessed by mutual adjust-
ment for the other MetS components as well as PLP,
due to its role in INF-γ stimulated inflammatory re-
sponses [2, 27] and hsCRP, due to its association with
low-grade inflammation. The adjusted means were
then back-transformed by exponentiating the natural-
log transformed means from the model. The associa-
tions between total neopterin and pre-defined cutoffs
of each component of MetS and the composite MetS
were also examined by calculating odds ratios (OR)
and 95 % confidence intervals (CI) in logistic regression
analysis, adjusted for age at blood collection (years), sex,
country, education (none or primary school completed,
technical or professional school, secondary school, above
secondary school, and not specified), smoking status
(never, former, current, and unknown), and physical
activity (low, medium, high, very high, missing). Total
neopterin was modeled in three categories according to
sex-specific tertiles. Tests for trend were performed by
modelling the median values of each category as a con-
tinuous variable. Subgroup analyses were performed by
age (<55, 50–65, and ≥65 years old), sex, and body mass
index (BMI, <30 and ≥30 kg/m2).
Analyses were performed using SAS 9.3. All tests were
two sided and statistical significance was assessed at the
level of 0.05.
Abbreviation
AGM: BP: blood pressure; CI: confidence interval; CV: coefficients of variance;
EPIC: European Prospective Investigation into Cancer and Nutrition;
HbA1c: glycated haemoglobin; HDLC: high-density lipoprotein cholesterol;
hsCRP: high-sensitivity C-reactive protein; IFN-γ: Interferon-gamma;
MetS: metabolic syndrome; OR: odds ratio; PLP: pyridoxal 5′-phosphate;
TG: Triglycerides.
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